{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:27:37Z","timestamp":1793406457933,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jgar.2024.05.014","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T13:28:06Z","timestamp":1717594086000},"page":"140-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5767-4441","authenticated-orcid":false,"given":"Julien","family":"Massol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Jeannot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Bouchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Potron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6596-7384","authenticated-orcid":false,"given":"Laurent","family":"Dortet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Jehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.05.014_bib0001","unstructured":"Global AMR R&D Hub; Incentivising the Development of New Antibacterial Treatments 2023; World Health Organization (WHO) 2023"},{"key":"10.1016\/j.jgar.2024.05.014_bib0016","unstructured":"Centers for Disease Control and Prevention (U.S.) Centers for Disease Control and Prevention (CDC) antibiotic resistance threats in the United States, 2019; Centers for Disease Control and Prevention (U.S.),"},{"key":"10.1016\/j.jgar.2024.05.014_bib0002","series-title":"U.S. Impact on Antimicrobial Resistance, Special Report 2022","year":"2022"},{"key":"10.1016\/j.jgar.2024.05.014_bib0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/mdr.2018.0014","article-title":"Spread of carbapenem and colistin-resistant klebsiella pneumoniae ST512 clinical isolates in Israel: a cause for vigilance","volume":"25","author":"Lalaoui","year":"2019","journal-title":"Microbial Drug Resistance"},{"key":"10.1016\/j.jgar.2024.05.014_bib0004","first-page":"226","article-title":"Dissemination of Carbapenemases producing gram negative bacteria in the Middle East","volume":"7","author":"Zahedi-bialvaei","year":"2015","journal-title":"Iran J Microbiol"},{"key":"10.1016\/j.jgar.2024.05.014_bib0005","unstructured":"European Centre for Disease Prevention and Control (ECDC) Healthcare-Associated Infections Acquired in Intensive Care Units - Annual Epidemiological Report for 2018; 2018."},{"key":"10.1016\/j.jgar.2024.05.014_bib0006","doi-asserted-by":"crossref","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.014_bib0007","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.014_bib0008","first-page":"230","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.014_bib0009","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.014_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by Carbapenem-Resistant Acinetobacter Baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.014_bib0011","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for Carbapenem-Resistant Acinetobacter Baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC-Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.05.014_bib0012","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/microorganisms11040984","article-title":"Cefiderocol-based versus colistin-based regimens for severe Carbapenem-Resistant Acinetobacter Baumannii infections: a propensity score-weighted, retrospective cohort study during the first two years of the COVID-19 pandemic","volume":"11","author":"Mazzitelli","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.jgar.2024.05.014_bib0013","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/antibiotics12040746","article-title":"Cefiderocol efficacy in a real-life setting: single-centre retrospective study","volume":"12","author":"Palermo","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2024.05.014_bib49","doi-asserted-by":"crossref","first-page":"106825","DOI":"10.1016\/j.ijantimicag.2023.106825","article-title":"Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19","volume":"62","author":"Russo","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.05.014_bib0048","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/antibiotics12061048","article-title":"Effectiveness of first-line therapy with old and novel antibiotics in ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter Baumannii: a real life, prospective, observational, single-center study","volume":"12","author":"Dalfino","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2024.05.014_bib0015","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jiph.2023.06.009","article-title":"Outcome of patients with Carbapenem-Resistant Acinetobacter Baumannii infections treated with cefiderocol: a multicenter observational study","volume":"16","author":"Cal\u00f2","year":"2023","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jgar.2024.05.014_bib0014","unstructured":"Real-world use of cefiderocol in the EU and US for Acinetobacter baumannii: interim data from the PROVE study, ECCMID. 2023, Copenhagen, Denmark. Session: 5c. New or repurposed antibacterial agents: clinical studies and trials. Poster session, ESCMID eLibrary. Available online: https:\/\/elibrary.escmid.org\/?search%5Bquery%5D=%22TIMSIT%22&tab=docs (accessed on 01.03.24)."},{"key":"10.1016\/j.jgar.2024.05.014_bib0017","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/14787210.2022.2020099","article-title":"All-cause mortality rates in adults with Carbapenem-resistant gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies","volume":"20","author":"Lodise","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2024.05.014_bib0018","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2024.05.014_bib0019","doi-asserted-by":"crossref","first-page":"e02371","DOI":"10.1128\/spectrum.02371-23","article-title":"Heteroresistance to cefiderocol in Carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-cr study was not linked to clinical outcomes: a post hoc analysis","volume":"11","author":"Longshaw","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2024.05.014_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02031-18","article-title":"In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.014_bib0021","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.jgar.2024.05.014_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01437-20","article-title":"Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection","volume":"65","author":"Kawaguchi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.014_bib0023","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","volume":"27","author":"Gatti","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.05.014_bib0024","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/biomedicines10030600","article-title":"Human serum proteins and susceptibility of Acinetobacter Baumannii to cefiderocol: role of iron transport","volume":"10","author":"Le","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jgar.2024.05.014_bib0025","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/jac\/dkz123","article-title":"Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects","volume":"74","author":"Katsube","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.05.014_bib0026","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jac\/dkv402","article-title":"In vitro antimicrobial activity of s-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting gram-negative bacteria","volume":"71","author":"Ito","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jgar.2024.05.014_bib0027","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02646-20","article-title":"In vitro antibacterial activity of cefiderocol against multidrug-resistant Acinetobacter baumannii","volume":"65","author":"Abdul-Mutakabbir","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.014_bib0028","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02712-21","article-title":"In vitro activity of cefiderocol against U.S. and European gram-negative clinical isolates collected in 2020 as part of the SENTRY antimicrobial surveillance program","volume":"10","author":"Shortridge","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2024.05.014_bib0029","first-page":"62","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016","author":"Hackel","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jgar.2024.05.014_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00877-21","article-title":"Contribution of PER-type and NDM-type \u03b2-lactamases to cefiderocol resistance in Acinetobacter baumannii","volume":"65","author":"Poirel","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.014_bib0031","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3390\/antibiotics11101352","article-title":"In vitro activity of cefiderocol and comparators against carbapenem-resistant gram-negative pathogens from France and Belgium","volume":"11","author":"Oueslati","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2024.05.014_bib0032","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00234-23","article-title":"Contribution of iron-transport systems and \u03b2-lactamases to cefiderocol resistance in clinical isolates of Acinetobacter Baumannii endemic to New York City","volume":"67","author":"Asrat","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.014_bib0033","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jgar.2020.07.009","article-title":"Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)","volume":"22","author":"Kohira","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.05.014_bib0034","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/AAC.01695-15","article-title":"In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains","volume":"60","author":"Kohira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.014_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-20","article-title":"Cefiderocol resistance in Acinetobacter Baumannii: roles of \u03b2-Lactamases, siderophore receptors, and penicillin binding protein 3","volume":"64","author":"Malik","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.014_bib0036","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00951-20","article-title":"Cefiderocol antimicrobial susceptibility testing considerations: the Achilles heel of the Trojan Horse?","author":"Simner","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jgar.2024.05.014_bib0037","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.diagmicrobio.2019.03.003","article-title":"Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth","volume":"94","author":"Hackel","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.014_bib0038","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/jac\/dkad149","article-title":"Performance evaluation of the UMIC\u24c7 cefiderocol to determine MIC in gram-negative bacteria","volume":"78","author":"Dortet","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.05.014_bib0039","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3390\/microorganisms11081971","article-title":"Performance of the disc diffusion method, MTS gradient tests and two commercially available microdilution tests for the determination of cefiderocol susceptibility in Acinetobacter Spp","volume":"11","author":"Jeannot","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.jgar.2024.05.014_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00966-20","article-title":"Comparison of agar dilution to broth microdilution for testing in vitro activity of cefiderocol against gram-negative bacilli","volume":"59","author":"Albano","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jgar.2024.05.014_bib50","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/jac\/dkac080","article-title":"Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing","volume":"77","author":"Matuschek","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.05.014_bib51","doi-asserted-by":"crossref","first-page":"e01649","DOI":"10.1128\/JCM.01649-20","article-title":"Cefiderocol antimicrobial susceptibility testing against multidrug-resistant gram-negative bacilli: a comparison of disk diffusion to broth microdilution","volume":"59","author":"Morris","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.05.014_bib52","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jalm\/jfac131","volume":"8","author":"Potter","year":"2023","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.jgar.2024.05.014_bib53","doi-asserted-by":"crossref","first-page":"e05355","DOI":"10.1128\/spectrum.05355-22","article-title":"Assessment of cefiderocol disk diffusion versus broth microdilution results when tested against Acinetobacter baumannii complex clinical isolates","volume":"11","author":"Liu","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2024.05.014_bib54","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10096-024-04745-7","volume":"43","author":"Bianco","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.014_bib0040","series-title":"M100Ed33 Performance Standards for Antimicrobial Susceptibility Testing","first-page":"346","year":"2023"},{"key":"10.1016\/j.jgar.2024.05.014_bib0041","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST) EUCAST: Warnings! 2023. Available online: https:\/\/www.eucast.org\/ast-of-bacteria\/warnings (accessed 09.09.23)."},{"key":"10.1016\/j.jgar.2024.05.014_bib0042","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01600-22","article-title":"Potential of inaccurate cefiderocol susceptibility results: a CLSI AST Subcommittee Advisory","volume":"61","author":"Simner","year":"2023","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.05.014_bib0044","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s10096-023-04691-w","article-title":"Rapid detection of cefiderocol susceptibility\/resistance in Acinetobacter Baumannii","volume":"42","author":"Raro","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.014_bib0045","article-title":"Physicochemical stability of cefiderocol, a novel siderophore cephalosporin, in syringes at 62.5 Mg\/mL for continuous administration in intensive care units","author":"Loeuille","year":"2021","journal-title":"Eur J Hospital Pharmacy"},{"key":"10.1016\/j.jgar.2024.05.014_bib0046","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40261-023-01257-8","article-title":"Feasibility of continuous infusion of cefiderocol in conjunction with the establishment of therapeutic drug monitoring in patients with extensively drug-resistant gram-negative bacteria","volume":"43","author":"Prinz","year":"2023","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jgar.2024.05.014_bib0047","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3390\/antibiotics11121830","article-title":"Pharmacokinetic of cefiderocol in critically ill patients receiving renal replacement therapy: a case series","volume":"11","author":"Mornese Pinna","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2024.05.014_bib55","doi-asserted-by":"crossref","first-page":"106852","DOI":"10.1016\/j.ijantimicag.2023.106852","article-title":"Pharmacokinetics\/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF)","volume":"62","author":"Gatti","year":"2023","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524001024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524001024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T09:41:53Z","timestamp":1726393313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524001024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":55,"alternative-id":["S2213716524001024"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.05.014","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}